Table 12.
Flare value measured by LFCM by treatment and visit (ITT)
| Day 1 | Day 3 | Day 7 | Day 14 | ||
|---|---|---|---|---|---|
| Nepafenac group | Mean | 20.6 | 20.6 | 13.4 | 11.4 |
| Std | 24.6 | 40.9 | 12.2 | 9.1 | |
| N | 101 | 103 | 103 | 103 | |
| Min | 0.5 | 0.3 | 0.4 | 0.3 | |
| Max | 153.2 | 396.7 | 57.8 | 57.8 | |
| Placebo group | Mean | 24.3 | 47.5 | 65.6 | 52.0 |
| Std | 34.4 | 49.8 | 77.7 | 69.9 | |
| N | 101 | 104 | 104 | 104 | |
| Min | 1.8 | 2.5 | 2.5 | 1.5 | |
| Max | 307.6 | 333.9 | 479.7 | 479.7 | |
| P value | 0.6201 | <0.0001 | <0.0001 | <0.0001 |
Non-baseline P values are LSMeans by visit; test = repeated measure ANOVA, main effect of treatment P < 0.0001; treatment by visit interaction P < 0.0001
Min minimum, Max maximum, Std standard deviation